Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016)
Cartesian Therapeutics' (RNAC) quarterly Other Accumulated Expenses came in at $831000.0 in Q2 2016, up 272.65% on a QoQ basis from $223000.0 in Q4 2015.
Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Other Accumulated Expenses data on file, last reported at $831000.0 in Q2 2016.
- On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $831000.0 in Q2 2016; TTM through Jun 2016 was $831000.0, a N/A change from a year earlier, with the FY2015 full-year figure at $223000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q2 2016 stood at $831000.0, up from $223000.0 in the prior quarter.
- Over the last five years, Other Accumulated Expenses for RNAC reached as high as $831000.0 in Q2 2016 and fell as low as $223000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Cartesian Therapeutics | 214.57 Mn | 214.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 831,000.00 |
| Dec 31, 2015 | 223,000.00 |